C. L. Beach

2.8k total citations
36 papers, 989 citations indexed

About

C. L. Beach is a scholar working on Hematology, Genetics and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, C. L. Beach has authored 36 papers receiving a total of 989 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Hematology, 13 papers in Genetics and 6 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in C. L. Beach's work include Acute Myeloid Leukemia Research (20 papers), Chronic Lymphocytic Leukemia Research (7 papers) and Multiple Myeloma Research and Treatments (5 papers). C. L. Beach is often cited by papers focused on Acute Myeloid Leukemia Research (20 papers), Chronic Lymphocytic Leukemia Research (7 papers) and Multiple Myeloma Research and Treatments (5 papers). C. L. Beach collaborates with scholars based in United States, France and Germany. C. L. Beach's co-authors include Jay T. Backstrom, Lewis R. Silverman, David R. McKenzie, Bercedis L. Peterson, James F. Holland, Richard A. Larson, Thomas M. Cosgriff, Mark G. Eller, Roger M. Lyons and Guido Marcucci and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Journal of the American College of Cardiology.

In The Last Decade

C. L. Beach

33 papers receiving 960 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
C. L. Beach United States 10 783 428 241 148 125 36 989
Gary Vanasse United States 15 299 0.4× 223 0.5× 245 1.0× 78 0.5× 58 0.5× 32 816
Jan Maxwell Nørgaard Denmark 17 724 0.9× 340 0.8× 229 1.0× 29 0.2× 298 2.4× 48 922
Elvira Deolinda Rodrigues Pereira Velloso Brazil 13 423 0.5× 184 0.4× 209 0.9× 24 0.2× 117 0.9× 81 654
Masashi Sawa Japan 14 456 0.6× 158 0.4× 77 0.3× 69 0.5× 157 1.3× 94 646
Jacques Troncy France 12 669 0.9× 504 1.2× 173 0.7× 33 0.2× 171 1.4× 34 1.0k
José D. González Spain 11 1.4k 1.8× 1.3k 3.1× 78 0.3× 29 0.2× 280 2.2× 18 1.6k
Jassada Buaboonnam Thailand 11 273 0.3× 167 0.4× 111 0.5× 57 0.4× 166 1.3× 28 571
Jieyu Ye China 14 375 0.5× 190 0.4× 76 0.3× 70 0.5× 128 1.0× 49 695
Kristen Pettit United States 12 320 0.4× 221 0.5× 187 0.8× 57 0.4× 64 0.5× 66 550
R. Hehlmann Germany 14 642 0.8× 102 0.2× 495 2.1× 65 0.4× 79 0.6× 28 887

Countries citing papers authored by C. L. Beach

Since Specialization
Citations

This map shows the geographic impact of C. L. Beach's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. L. Beach with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. L. Beach more than expected).

Fields of papers citing papers by C. L. Beach

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. L. Beach. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. L. Beach. The network helps show where C. L. Beach may publish in the future.

Co-authorship network of co-authors of C. L. Beach

This figure shows the co-authorship network connecting the top 25 collaborators of C. L. Beach. A scholar is included among the top collaborators of C. L. Beach based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. L. Beach. C. L. Beach is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Babiker, Hani M., Mohammed Milhem, Joseph Aisner, et al.. (2020). Evaluation of the bioequivalence and food effect on the bioavailability of CC-486 (oral azacitidine) tablets in adult patients with cancer. Cancer Chemotherapy and Pharmacology. 85(3). 621–626. 7 indexed citations
3.
OGASAWARA, K., Kathryn J. Newhall, Stephen E. Maxwell, et al.. (2019). Population Pharmacokinetics of an Anti-PD-L1 Antibody, Durvalumab in Patients with Hematologic Malignancies. Clinical Pharmacokinetics. 59(2). 217–227. 24 indexed citations
4.
Almeida, António, Pierre Fenaux, Guillermo Garcia‐Manero, et al.. (2018). Safety profile of lenalidomide in patients with lower-risk myelodysplastic syndromes without del(5q): results of a phase 3 trial. Leukemia & lymphoma. 59(9). 2135–2143. 5 indexed citations
5.
Santini, Valeria, António Almeida, Aristoteles Giagounidis, et al.. (2017). The Effect of Lenalidomide on Health-Related Quality of Life in Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes: Results From the MDS-005 Study. Clinical Lymphoma Myeloma & Leukemia. 18(2). 136–144.e7. 15 indexed citations
6.
7.
8.
Mahmoud, Dalia, et al.. (2012). Quality of Life and Productivity Impact of Myelodysplastic Syndromes (MDS): The Patient Perspective. Blood. 120(21). 4705–4705. 1 indexed citations
9.
Hellström‐Lindberg, Eva, Pierre Fenaux, G J Mufti, et al.. (2008). Relationship of progression to acute myeloid leukemia (AML) from myelodysplastic syndrome (MDS) and cytogenetic status. Journal of Clinical Oncology. 26(15_suppl). 7089–7089. 1 indexed citations
10.
Lyons, Roger M., Thomas M. Cosgriff, Sanjiv Modi, et al.. (2006). Hematologic Improvement, Transfusion Independence, and Safety Assessed Using Three Alternative Dosing Schedules of Azacitidine in Patients with Myelodysplastic Syndromes.. Blood. 108(11). 2662–2662. 2 indexed citations
11.
Silverman, Lewis R., David R. McKenzie, Bercedis L. Peterson, et al.. (2006). Further Analysis of Trials With Azacitidine in Patients With Myelodysplastic Syndrome: Studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. Journal of Clinical Oncology. 24(24). 3895–3903. 419 indexed citations
12.
Marcucci, Guido, et al.. (2005). Bioavailability of Azacitidine Subcutaneous Versus Intravenous in Patients With the Myelodysplastic Syndromes. The Journal of Clinical Pharmacology. 45(5). 597–602. 117 indexed citations
13.
14.
Heller, Gary V., et al.. (1997). Antianginal Response to Once‐Daily Diltiazem CD in Patients Receiving Concomitant β‐Blockers, Long‐Acting Nitrates, or Both. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 17(4). 760–766. 3 indexed citations
15.
Lewin, Andrew, et al.. (1997). Long‐Acting Diltiazem CD Is Safe and Effective in a Hypertensive Mexican‐American Population. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 17(6). 1254–1259. 7 indexed citations
16.
Blackshear, Joseph L., Bruce S. Stambler, William Strauss, et al.. (1996). Control of heart rate during transition from intravenous to oral diltiazem in atrial fibrillation or flutter. The American Journal of Cardiology. 78(11). 1246–1250. 10 indexed citations
17.
Beach, C. L., et al.. (1995). Inter-rater reliability of a paediatric outcome measure in Nepal. International Journal of Rehabilitation Research. 18(1). 45–53. 3 indexed citations
18.
Thadani, Udho, et al.. (1991). Diltiazem sustained release plus nitrates versus nitrate therapy alone for the treatment of stable angina pectoris. Journal of the American College of Cardiology. 17(2). A108–A108. 2 indexed citations
19.
Beach, C. L., et al.. (1988). Clinical Assessment of a Two-Compartment Bayesian Forecasting Method for Lidocaine. Therapeutic Drug Monitoring. 10(1). 74–79. 3 indexed citations
20.
Woolf, L. I., et al.. (1974). Impaired gluconeogenesis in dogs with E. coli bacteremia.. PubMed. 76(4). 533–41. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gary Vanasse Breakdown of academic impact, for papers by Jan Maxwell Nørgaard Breakdown of academic impact, for papers by Elvira Deolinda Rodrigues Pereira Velloso Breakdown of academic impact, for papers by Masashi Sawa Breakdown of academic impact, for papers by Jacques Troncy Breakdown of academic impact, for papers by José D. González Breakdown of academic impact, for papers by Jassada Buaboonnam Breakdown of academic impact, for papers by Jieyu Ye Breakdown of academic impact, for papers by Kristen Pettit Breakdown of academic impact, for papers by R. Hehlmann
Rankless by CCL
2026